DNA methylation plays an important and dynamic role in regulating gene expression. It allows cells to suppress expression of viral and nonhost DNA elements, and facilitates response to environmental stimuli. Aberrant DNA methylation (hyper- or hypomethylation) and its impact on gene expression have been implicated in many biological processes and diseases. Methylation arrays enable quantitative interrogation of selected methylation sites across the genome, offering high-throughput capabilities that minimize the cost per sample.
Our Infinium MethylationEPIC and Mouse Methylation BeadChips allow you to interrogate 850,000 or 285,000 markers, respectively, across the genome at single-nucleotide resolution.
Powered by the Infinium assay, the MethylationEPIC BeadChip is ideal for epigenome-wide association studies (EWAS), tumor profiling, and various cell biology experiments. It offers comprehensive, expert-selected coverage, including 99% of RefSeq genes, 95% of CpG islands, high coverage of enhancer regions, and other content categories. With > 90% of the original content from the Infinium HumanMethylation450K covered, the MethylationEPIC kit supports the next generation of epigenetics research.
Also leveraging the Infinium assay, the Mouse Methylation BeadChip can be used in EWAS and other experiments probing the methylome in healthy and diseased tissues. Much like the MethylationEPIC BeadChip, the Mouse Methylation BeadChip offers genome-wide coverage, with probes targeted to CpG islands, enhancer regions, transcription start sites, and other important regions of the methylome.
Our methylation microarrays combine comprehensive coverage and high-throughput capabilities. Advantages include:
Our methylation arrays follow a user-friendly, streamlined workflow, enabling processing of up to 96 samples simultaneously from low sample input (as little as 250 ng).
Offering quantitative measurement at the single-CpG-site level, these methylation microarrays offer powerful resolution for understanding epigenetic changes.
Click on the below to view products for each workflow step.
Robust methylation profiling microarray with extensive coverage of CpG islands, genes, and enhancers. Use for epigenome-wide association studies and other experiments.
Features > 285k markers across the methylome for high resolution epigenetic analyses of diverse murine strains.
Supports high-throughput BeadChip processing, scanning hundreds to thousands of samples quickly and accurately.
Perform next-generation sequencing and methylation array scanning all on one platform.
Effortless differential methylation analysis and display of chromosomal coordinates, % GC, location in CpG island, and methylation ß values.
Explore a variety of methods used to detect cytosine modifications, including methylation arrays, and learn more about the impact of cytosine methylation.
Read GuideDr. Sundberg at the Karolinska Institute uses methylation arrays and RNA-Seq to reveal exercise-related epigenetic changes.
Read InterviewDr. Mill at King’s College London uses methylation arrays to identify epigenetic changes that contribute to neurodegenerative disorders.
Read InterviewDr. Samani at University of Leicester uses methylation arrays to identify cell signaling disruption linked with high BMI.
Read InterviewMethylation array studies enable researchers to understand the functional mechanisms at work in complex disease. Illumina offers complementary solutions for researchers studying these disorders. Learn more about complex disease research.
Illumina array and sequencing solutions are ideal for detecting altered methylation patterns and epigenetic changes that provide insight into tumorigenic pathways and cancer progression. Learn more about cancer epigenetics.
Methylation sequencing approaches offer higher density and flexibility in assessing epigenome changes.
Illumina experts provide methylation array and genotyping services.
Experts describe their approaches to analyzing Illumina methylation array data.
Epigenetic changes in newborns linked with maternal smoking during pregnancy.